Treating cancer from the inside out®
Game-changing therapies at the forefront of innovation in radiopharmaceutical cancer therapy
About
Perspective Therapeutics is on a mission to transform cancer treatment with targeted alpha particle therapy
Perspective Therapeutics is a radiopharmaceutical company dedicated to developing image-guided, targeted alpha-particle therapies (TATs) for the treatment of cancer.
Technology
Our radioisotope technology delivers radiation at a cellular level
Our revolutionary Pb-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation directly to cancer cells utilizing high-affinity targeting peptides.
In contrast to conventional radiotherapy, this approach targets more potent alpha particles directly to tumor cells, delivering significantly higher energy at a shorter range. Due to its short half-life, the rapid decay of Pb-212 leads to potentially greater tumor cell killing while avoiding the emergence of resistance and limiting the damage to healthy tissue.
In addition, our image-guided theranostics platform allows physicians to confirm tumor target expression and off-target distribution prior to treatment to assist with patient selection and optimize outcomes.
Perspective Therapeutics uses proprietary targeting peptides conjugated to radioisotopes via a proprietary Pb-specific chelator to image tumors, and then deliver alpha-particle radiopharmaceuticals to attack them on a cellular level.
Therapy
Therapeutic Areas
Pipeline
Oncology pipeline of image-guided alpha-particle radiotherapies
Most programs leverage the chemically matched isotope pair Pb-203/212 conjugated to high-affinity, tumor-specific peptides for image-guided alpha particle cancer therapies.
| PROGRAM (TARGET) |
TARGET DISEASE | CANDIDATE EVALUATION | HUMAN CLINICAL IMAGING | PHASE 1/2 | REGISTRATION ENABLING STUDY | STATUS |
|---|---|---|---|---|---|---|
| VMT01/02 (MC1R) |
Melanoma (MC1R Imaging & Therapy) |
|
Next cohort is open for enrollment
Enrolling |
|||
| VMT-α-NET (SSTR2) |
Neuroendocrine Tumors Other SSTR2 Expressing Tumors |
|
Cohort 2: Enrolling Cohort 3: Pending FDA alignment Under evaluation |
|||
| PSV359 (FAP-α) |
Multiple Solid Tumors | Cohort 1: Enrolling | ||||
| PSV4XX (PSMA) | Prostate (PSMA Imaging & Therapy) |
Under evaluation | ||||
| Undisclosed Program 5 | Multiple Solid Tumors | Under evaluation | ||||
| Undisclosed Program 6 | Multiple Solid Tumors | Under evaluation | ||||
| Undisclosed Program 7 | Multiple Solid Tumors | Under evaluation | ||||
| Pre-Targeting Platform | Multiple Solid Tumors | Under evaluation | ||||